Abdulghany I. Usman Jr.

September 2019
BSN 3-A

DRUG NAME

GENERIC NAME: Ceftriaxone

BRAND NAME: Rocephin

CLASSIFICATION SIDE
Therapeutic: anti-infectives EFFECT
Pharmacologic: third-generation cephalosporins S/
MECHANISM OF ACTION ADVERS
E
Binds to the bacterial cell wall membrane, causing cell death. Therapeutic Effects:
EFFECT
Bactericidal action against susceptible bacteria. Spectrum:Similar to that of S
second-generation cephalosporins, but activity against staphylococci is less, while
activity against gram-negative pathogens is greater, even for organisms resistant to CNS:
first- and second-generation agents. Notable is increased action against: Acinetobacter,
 S
Enterobacter, Haemophilus influenzae (including -lactamase-producing e
i
strains), Haemophilus parainfluenzae, Escherichia coli, Klebsiella pneumoniae,
z
Morganella morganii, Neisseria, Proteus, Providencia,Serratia,Moraxella catarrhalis. Has u
r
some activity against anaerobes, includingBacteroides fragilis. Not active
e
against methicillin-resistant staphylococci or enterococci. s
GI:
 P
s
e
u
d
o
m
e
m
b
r
a
n
 o
u
s
C
o
l
i
t
i
s
 D
i
a
r
r
h
e
a
 C
h
o
l
e
l
i
t
h
i
a
s
e
s
 G
a
l
l
b
l
a
d
d
e
r
s
l
u
d
g
Abdulghany I. Usman Jr. September 2019
BSN 3-A

i
n
g
Derm:
 R
a
s
h
e
s

U
r
t
i
c
a
r
i
a
.
Hemat:
 b
l
e
e
d
i
n
g
,
 e
o
s
i
n
o
p
h
i
l
i
a
,
 h
e
m
 o
l
y
t
i
c
a
n
e
m
i
a
,
 l
e
u
k
o
p
e
n
i
a
,
 t
h
r
o
m
b
o
c
y
t
o
s
i
s
Local:

 p
a
i
n
a
t
I
M
Abdulghany I. Usman Jr. September 2019
BSN 3-A

s
i
t
e
,
p
h
l
e
b
i
t
i
s
a
t
I
V
s
i
t
e
Misc:
 a
l
l
e
r
g
i
c
r
e
a
c
t
i
o
n
s
i
n
c
l
u
d
i
n
 g
a
n
a
p
h
y
l
a
x
i
s
 S
u
p
e
r
i
n
f
e
c
t
i
o
n
.
INDICATIONS NURSIN
Treatment of: Skin and skin structure infections, Bone and joint infections, Complicated G
and uncomplicated urinary tract infections, Uncomplicated gynecological infections RESPO
including gonorrhea, Lower respiratory tract infections, Intra-abdominal infections, NSIBILI
Septicemia, Meningitis, Otitis media. Perioperative prophylaxis. TIES
CONTRAINDICATIONS
Hypersensitivity to cephalosporins; Serious hypersensitivity ASSESS
to penicillins; MENT
Pedi: Neonates 28 days (use in hyperbilirubinemic neonates may 1. A
lead to kernicterus); Pedi: Neonates s
s
28 days requiring calcium-containingIV solutions (qrisk of precipitation formation). e
DOSAGE s
s
IM, IV (Children): f
o
Most infections—50– 75 mg/kg/day (not to exceed 2 g/day) divided every 12– 24 hr. r
i
Meningitis—100 mg/kg/day (not to exceed 4 g/day) divided every 12– 24 hr or n
Uncomplicated gonorrhea—125 mg IM (single dose). f
e
Abdulghany I. Usman Jr. September 2019
BSN 3-A

Acute otitis media—50 mg/kg (not to exceed 1 g) IM single dose. c

t
i
o
n
(
v
i
t
a
l
s
i
g
n
s
;
a
p
p
e
a
r
a
n
c
e
o
f
w
o
u
n
d
,
s
p
u
t
u
m
,
u
r
i
n
e
,
 a
n
d
s
t
o
o
l
;
W
B
C
)
a
t
b
e
g
i
n
n
i
n
g
o
f
a
n
d
t
h
r
o
u
g
h
o
u
t
t
h
e
r
a
p
y
2.
B
Abdulghany I. Usman Jr. September 2019
BSN 3-A

e
f
o
r
e
i
n
i
t
i
a
t
i
n
g
t
h
e
r
a
p
y
,
o
b
t
a
i
n
a
h
i
s
t
o
r
y
t
o
d
e
t
e
r
m
i
n
e
p
r
e
v
i
o
u
s
u
s
e
o
f
a
n
d
r
e
a
c
t
i
o
n
s
t
o
p
e
n
i
c
i
l
l
i
n
s
o
r
c
e
p
h
a
l
o
s
Abdulghany I. Usman Jr. September 2019
BSN 3-A

p
o
r
i
n
s
.
P
e
r
s
o
n
s
w
i
t
h
a
n
e
g
a
t
i
v
e
h
i
s
t
o
r
y
o
f
p
e
n
i
c
i
l
l
i
n
s
e
 n
s
i
t
i
v
i
t
y
m
a
y
s
t
i
l
l
h
a
v
e
a
n
a
l
l
e
r
g
i
c
r
e
s
p
o
n
s
e
.
3. O
b
t
a
i
n
s
p
Abdulghany I. Usman Jr. September 2019
BSN 3-A

e
c
i
m
e
n
s
f
o
r
c
u
l
t
u
r
e
a
n
d
s
e
n
s
i
t
i
v
i
t
y
b
e
f
o
r
e
i
n
i
t
i
a
t
i
n
g
t
h
e
r
a
p
y
.
F
i
r
s
t
d
o
s
e
m
a
y
b
e
g
i
v
e
n
b
e
f
o
r
e
r
e
c
e
i
v
i
n
g
r
e
s
u
l
t
Abdulghany I. Usman Jr. September 2019
BSN 3-A

s
.
4. P
e
d
i
:
A
s
s
e
s
s
n
e
w
b
o
r
n
s
f
o
r
j
a
u
n
d
i
c
e
a
n
d
h
y
p
e
r
b
i
l
i
r
u
b
i
n
e
m
i
a
;
c
a
n
i
n
c
r
e
a
s
e
b
i
l
i
r
u
b
i
n
e
m
i
a
a
n
d
s
h
o
u
l
d
n
o
t
b
e
a
d
m
i
Abdulghany I. Usman Jr. September 2019
BSN 3-A

n
i
s
t
e
r
e
d
t
o
j
a
u
n
d
i
c
e
d
n
e
o
n
a
t
e
s
,
e
s
p
e
c
i
a
l
l
y
p
r
e
m
a
t
u
r
e
n
 e
o
n
a
t
e
s
.
5. O
b
s
e
r
v
e
p
a
t
i
e
n
t
f
o
r
s
i
g
n
s
a
n
d
s
y
m
p
t
o
m
s
o
f
a
n
a
p
h
Abdulghany I. Usman Jr. September 2019
BSN 3-A

y
l
a
x
i
s
(
r
a
s
h
,
p
r
u
r
i
t
u
s
,
l
a
r
y
n
g
e
a
l
e
d
e
m
a
,
w
h
e
e
z
i
n
g
)
.
D
i
s
c
o
n
t
i
n
u
e
t
h
e
d
r
u
g
a
n
d
n
o
t
i
f
y
h
e
a
l
t
h
c
a
r
e
p
r
o
f
e
s
s
i
o
n
a
l
i
Abdulghany I. Usman Jr. September 2019
BSN 3-A

m
m
e
d
i
a
t
e
l
y
i
f
t
h
e
s
e
s
y
m
p
t
o
m
s
o
c
c
u
r
.
K
e
e
p
e
p
i
n
e
p
h
r
i
n
e
,
a
n
a
n
t
i
h
i
s
t
a
m
i
n
e
,
a
n
d
r
e
s
u
s
c
i
t
a
t
i
o
n
e
q
u
i
p
m
e
n
t
c
l
o
s
e
b
y
i
Abdulghany I. Usman Jr. September 2019
BSN 3-A

n
t
h
e
e
v
e
n
t
o
f
a
n
a
n
a
p
h
y
l
a
c
t
i
c
r
e
a
c
t
i
o
n
.
6. M
o
n
i
t
o
r
b
o
w
e
l
f
u
n
c
t
i
o
n
.
D
i
a
r
r
h
e
a
,
a
b
d
o
m
i
n
a
l
c
r
a
m
p
i
n
g
,
f
e
v
e
r
,
a
n
d
b
l
o
o
d
Abdulghany I. Usman Jr. September 2019
BSN 3-A

y
s
t
o
o
l
s
s
h
o
u
l
d
b
e
r
e
p
o
r
t
e
d
t
o
h
e
a
l
t
h
c
a
r
e
p
r
o
f
e
s
s
i
o
n
a
l
p
r
o
m
p
t
l
y
a
s
a
s
i
g
n
o
f
p
s
e
u
d
o
m
e
m
b
r
a
n
o
u
s
c
o
l
i
t
i
s
.
M
a
y
b
e
g
i
n
Abdulghany I. Usman Jr. September 2019
BSN 3-A

u
p
t
o
s
e
v
e
r
a
l
w
e
e
k
s
f
o
l
l
o
w
i
n
g
c
e
s
s
a
t
i
o
n
o
f
t
h
e
r
a
p
y
.
7. L
a
b
T
e
s
t
C
o
n
s
i
d
e
r
a
t
i
o
n
s
:
M
a
y
c
a
u
s
e
p
o
s
i
t
i
v
e
r
e
s
u
l
t
s
f
o
r
C
o
o
m
Abdulghany I. Usman Jr. September 2019
BSN 3-A

b
s
’
t
e
s
t
.
8.
M
a
y
c
a
u
s
e
i
n
c
r
e
a
s
e
d
s
e
r
u
m
A
S
T
,
A
L
T
,
a
l
k
a
l
i
n
e
 p
h
o
s
p
h
a
t
a
s
e
,
b
i
l
i
r
u
b
i
n
,
L
D
H
,
B
U
N
,
a
n
d
c
r
e
a
t
i
n
i
n
e
.
9.
M
a
y
Abdulghany I. Usman Jr. September 2019
BSN 3-A

r
a
r
e
l
y
c
a
u
s
e
l
e
u
k
o
p
e
n
i
a
,
n
e
u
t
r
o
p
e
n
i
a
,
a
g
r
a
n
u
l
o
c
y
t
o
s
i
s
,
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
,
e
o
s
i
n
o
p
h
i
l
i
a
,
l
y
m
p
h
o
c
y
t
o
s
i
s
,
a
n
Abdulghany I. Usman Jr. September 2019
BSN 3-A

d
t
h
r
o
m
b
o
c
y
t
o
s
i
s
.
Reference:

Valerand, A.H.,& Sanoski, C.A. Davis’s Drug Guide for Nurses (15th) [pdf]